Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS

New England Journal of Medicine

Volumn 334, Issue 23, 1996, Pages 1491-1497

  Spector, Stephen A ^a   Mckinley, George F ^b   Lalezari, Jacob P ^c,d   Samo, Tobias ^e   Andruczk, Robert ^f   Follansbee, Stephen ^g   Sparti, Paula D ^h   Havlir, Diane V ^a   Simpson, Gail ^a,i   Buhles, William ^j   Wong, Rodney ^j   Stempien, Mary Jean ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Methodist Hospital   (United States)

^f Oaklawn Physicians Group   (United States)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h Cormmunity Res Initiative S F ^*  (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j ROCHE BIOSCIENCE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ANOREXIA; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HUMAN; HUMAN CYTOMEGALOVIRUS; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; GANCICLOVIR; HUMANS; MALE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 9344267138     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199606063342302     Document Type: Article

References (33)

1. Reichert CM, O'Leary TJ, Levens DL, Simrell CR, Macher AM. Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol 1983; 112:357-82.
2. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992;14:608-15.
3. Jacobson MA, Mills J. Serious Cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988;108:585-94.
4. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994;120:932-44.
5. Lane HC, Laughon BE, Falloon J, et al. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994;120:945-55. [Erratum, Ann Intern Med 1995;122:317.]
6. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107:75-80.
7. Bloom JN, Palestine AG. The diagnosis of Cytomegalovirus retinitis. Ann Intern Med 1988;109:963-9.
8. Goodgame RW. Gastrointestinal Cytomegalovirus disease. Ann Intern Med 1993;119:924-35.
9. Morgello S, Cho E-S, Nielsen S, Devinsky O, Petito CK. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol 1987;18: 289-97.
10. Kalayjian RC, Cohen ML, Bonomo RA, Flanigan TP. Cytomegalovirus ventriculoencephalitis in AIDS: a syndrome with distinct clinical and pathologic features. Medicine (Baltimore) 1993;72:67-77.
11. Alford CA, Britt WJ. Cytomegalovirus. In: Fields BN, Knipe DM, eds. Virology. 2nd ed. New York: Raven Press, 1990;1981-2010.
12. Collaborative DHPG Treatment Study Group. Treatment of serious Cytomegalovirus infections with 9-(l,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314: 801-5.
13. Spector SA, Weingeist T. Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for Cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-63.
14. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for Cytomegalovirus retinitis. N Engl J Med 1992;326:213-20. [Erratum, N Engl J Med 1992; 326:1172.]
15. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of Cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989;33:736-41.
16. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of Cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73.
17. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995;171:1431-7.
18. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
19. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9:471-7.
20. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. N Engl J Med 1992;327:1842-8.
21. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
22. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
23. Masur H, Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex, Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;329: 898-904.
24. Powderly WG, Finkelstein CM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
25. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:Suppl: 1S-5S.
26. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984;5:348-61.
27. Kim K, Tsiatis AA. Study duration for clinical trials with survival response and early stopping rule. Biometrics 1990;46:81-92.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324:1005-11.
30. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992;326:1182-6.
31. Brosgart CL, Craig C, Hillman D, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease in HIV-infected individuals with severe immunosuppression. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995. abstract.
32. Gerna G, Parea M, Percivalle E, et al. Human cytomegalovirus viraemia in HIV-l-seropositive patients at various clinical stages of infection. AIDS 1990;4:1027-31.
33. Spector SA, Merrill R, Wolf D, Dankner WM. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992;30:2359-65.